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In patients with a history of renal disease the kidney shows a gradual, in most cases
linear, loss of function even when the underlying kidney disease has been cured.
However, the rate of renal function deciine shows a large interindividual variation. The
independency of this process suggests that not the renal disease itself but other factors
are responsible. In the past decades, many of those factors have been identified. One of
the most important of these modifying factors is a change in renal hemodynamics
leading to a rise in intraglomerular pressure. In situations where a large number of
nephrons are removed or malfunctioning due to underlying disease, the kidney tries to
maintain filtration by increasing the pressure in the remaining healthy nephrons through
afferent vasodilatation, efferent vasoconstriction or both. The renin-angiotensin system,
which if often activated in renal disease, plays an importzurt role in inducing these renal
hemodynamic chzurges. However, this short-term beneficial compensatory hemodynamic
mechanism appears to be deleterious in the long-term: the increased intraglomerular
pressure induces focal and segmental glomerulosclerosis, which may eventually lead to
end-stage renal failure. In recent years, many measures aiming at prevention or
amelioration of renal function decline have been studied. Counteracting the renin-
angiotensin system with angiotensin-converting-enzyme inhibitors (ACE inhibitors) is
among the most promising of these measures. These drugs have been shown to be
beneficial in many animal models. However, in humans their effectivity is less
convincing and prospective trials are ongoing. One of these trials was started in
Groningen, in 1988, comparing the ACE inhibitor enalapril and the B-blocker atenolol
with respect to their effect on long-term renal function decline.
Chapter 2.
This chapter gives an overview of the management of chronic renal failure. Apart from
intraglomerular pressure elevation several other possible causes of progressive renal
function loss are mentioned. Animal data on progressive renal function loss may to a
certain extent be extrapolated to the clinical setting.
Next, various interventions aiming at halting the progression of renal function loss are
discussed. lmmunosuppressive therapy has been used in renal diseases with
immunologic mechanisms of disease progression. In other renal diseases, their vaiue is
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sti l l  debated. Even if immunosuppression is shown to slow renal function decline, a
comparison with alternative therapies is necessary because of the relative dangers of the
former. Antihypertensive therapy has been shown to be beneficial in several studies in
patients with renal disease, especially in diabetes. Dietary protein-restriction has been
found to retard renal function decline in the first prospective studies, although a recent
large multicenter study (Modification of Diet in Renal Disease, MDRD) found no
significant protective effect in patients with renal insufficiency. ACE inhibitors possess
an additive renal protective effect over conventional antihypertensive therapy, as shown
in several recent studies. However, most of these studies were small, retrospective or
non-randomized. Larger multicenter trials eue ongoing. Proteinuria by itself may play a
direct role in causing pro-eressive renal function deterioration. Thus, the antiproteinuric
effect of different therapeutic regimens may be renoprotective only by reducing the
protein load of the nephrons. However. since it is hard to dissociate the antiproteinuric
effect of these regimens from their concomitant effects on glomerular hemodynamics,
it remains unproven whether the direct reduction in nephron protein load is responsible
for the renal protective effect. Clinical evidence that an antiproteinuric effect prevents
renal function loss is l imited. Evidence is growing that l ipid-lowering agents might be
renoprotective.
Chapter 3.
In this study the antihypefiensive and renal effects of the ACE inhibitor lisinopril were
studied in a group of patients with impaired renal function and hypertension. After
twelve weeks of treatment most of the patients showed a good blood pressure response
to lisinopril. During this period, both glomerular filtration rate (GFR) and filtration
fraction (FF) fell by approxinately 20 7o whereas effective renal plasma flow (ERPF)
remained stable. During a one-year follow-up period, the l isinopril dose could be
lowered gradually in a subset of patients with a stable diastolic blood pressure, without
losing the antihypertensive effect. With respect to renal hemodynamics, GFR decreased
in two thirds of the patients, whereas GFR remained fairly stable in the other third. Ín
this latter group the pre-treatment GFR was higher and the effective renal plasma flow
had increased. In contrast, in the group with a decline in GFR, pretreatment GFR was
lower, and lisinopril had induced a decrease in ERPF without any change in FF. Thus,
the ACE inhibitor lisinopril is an effective antihypertensive drug in patients with renal
function impairment. Interestingly, lisinopril increases ERPF and stabilizes GFR in the
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subgroup of patients with a higher pre-treatment GFR, which could suggest that therapy
should be started early to reach an optimal renoprotective effect'
Chapter 4
In this chapter the question is addressed whether there are quantitative differences
between different ACE inhibitors with respect to their influence on renal versus systemic
hemodynamics. Such a difference could guide the choice for a specific ACE inhibitor
in certain disease conditions. A single-blind cross-over study was performed in 8 patients
with essential hypertension and normal renal function, comparing the ACE inhibitors
enalapril .md lisinopril. Interestingly, with the same blood pressure reduction, ERPF rose
more on enalapril than on lisinopril. Likewise, filtration fraction (FF) and renal vascular
resistance (RVR) decreased more on enalapril than on lisinopril. Counteracting these
ACE- inhibitor-incluced changes by angiotensin II infusion resulted in a more marked
response of ERPF, FF turd RVR during enalapril as compared to lisinopril. We
concluded that in a situation of a comparable systemic blood pressure reduction,
enalapril has a greater effect on renal hemodynamics than lisinopnl. Enalapnl could thus
be a more effective renoprotective antihypertensive drug.
Chapter 5
In chapter 5 the question is addressed whether the antiproteinuric effect of an ACE
inhibitor is solely due to its bloocl pressure lowering effect or to its specific effects on
the kidney. Therefore, the antihypertensive, renal hemodynamic and antiproteinuric
effects of the ACE inhibitor enalapril and the B-blocker atenolol were compared in a
prospective, ranclomised, double blind study in 21 patients with proteinuria of non-
diabetic origin, hypertension and moderately impaired renal function. The fall in systolic
and diastolic bloocl pressure was not different between both groups. However, although
mean proteinuria fell slightly during atenolol, the falt that was observed during enalapril
treatment was significantly 
-ereater. In both groups filtration fraction fell, the fall being
greater on enalapril than on atenolol. We concluded that enalapril lowers proteinuria
more than atenolol in patients with non-diabetic renal disease, despite a similar blood
pressure lowering effect of both drugs. This antiproteinuric effect of angiotensin
conveÍing enzyme inhibitors appears to be associated with the characteristic renal




Reliable measurement of renal function is of paramount importance in long-term
intervention studies on the progression of chronic renal failure. Sequential accurate
determination of glomerular filtration rate (GFR) measuring the renal clearances of
exogenous tracers such as iothalamate is the most accepted method in this respect.
However, due to inaccuracies in urine collection without bladder cathelerisation, intratest
variation, and thus intertest variation, of this gold standard UV/P method is considerable.
This impacts on the accuracy of long-term slope estimations. A previously described
method of GF'R determination based on simultaneous infusion of 13tl-hippuran and r25l-
iothalamate has been shown to correct for inaccurate urine coilection. To investigate
whether this combined infusion method indeed improves the accuracy of GFR
measurements and thus improves GFR slope accuracy in intervention trials, we zuralyzed
longitudinal GFR data obtained in 71 patients with renal disease, during a follow-up of
84 to 180 weeks. The correction method yielded an almost five times smaller intra-test
coefficient of variation (CV) and a twice smaller inter-test CV than the standard method.
These smaller CV's in GFR measurements using the correction method had a clear
impact on slope accuracy. All error parameters of the regression equation were
significantly smaller using corrected GFR. Also, the range of slopes was almost twice
as low using the correction method. Interestingly, the improvement reduced the
necessary sample size needed to detect a certain difference between different
interventions to about 30Vo of the necessary sample size when using the standard
method. We conclude that the accuracy of GFR measurements is improved using the
hippuran correction method. The resulting improvement greatly enhances the accuracy
of long-term GFR-slope calculations. A possible difference between two treatment
modalities may thus be detected more rapidly using this corrected GFR measurement
method.
Chapter 7
Not all patients with impaired renal function respond equally well to therapy aiming at
prevention of further renal function deterioration. Therefore, nlarkers predictive for a
good response to therapy, which can be evaluated at the start of treatment or directly
thereafter could be of value. One of those markers could be the initial antiproteinuric
effect of a ceÍain intervention. Thus, we evaluated whether the short-term antiproteinuric
































predictive for a long-term beneficial effect on renal function decline. Twenty-nine
patients with proteinuria and impaired renal function were treated with enalapril or
atenolol. After 12 weeks treatment FF and proteinuria had fallen significantly. A great
interindividual difference in antiproteinuric response was noticed. During long-term
follow up a fall in mean GFR was observed with considerable interindividual variation.
The slope of this GFR decline correlated with the short term responses of proteinuria
and filtration fraction, but not with the blood pressure response. We conclude that the
magnitude of the initial reduction in proteinuria and filtration fraction induced by either
enalapril or atenolol predicts the effect of that treatment on long-term GtrR decline. This
observation may be important in identifying responders to continued treatment in an
early phase as far as renal function protection is concerned.
Chapter 8
In this chapter we focus on a possible other predictive marker for treatment response in
long-term intervention studies: the initial decline in GFR which may occur after starting
therapy. Such an initial change in GFR is suggested to be the result of a treatment-
induced intraglomerular pressure fall. If so, it should be reversible after treatment
withdrawal. Moreover, the magnitude of such a hemodynamic change could predict
whether long term renal protection will occur during continued treatment. We therefore
investigated 40 hypertensive non-diabetic patients with impaired renal function, who
were enrolled in a double blind intervention trial. After a placebo baseline period they
were randomly assigned to treatment with either atenolol or enalapril. Study parameters
were measured at baseline, after 12 weeks (treatment titration), each subsequent 24
weeks during follow-up, and 12 weeks after treatment withdrawal. Mean GFR fell rather
steep during the first l2 weeks and showed a less steep decline during follow-up. The
initial acute treatment induced decline in GFR correlated with the long-term GFR slope
: the more initial GFR fall, the better the long-term slope. After 4 years of treatment,
withdrawal for 12 weeks resulted in a significemt rise in GFR. The initial fall in GFR
was related to the rise after withdrawal. The patients were divided in a group A that
showed an initial fall in GFR and a group B in whom GFR initially did not change'
Group A had a significantly less steep slope than group B. In group A GFR increased
again after withdrawal of treatment, whereas it did not in group B. As a consequence'
GFR post-treatnent was not different compared to pre-treatment in group A, whereas
it was significantly lower in group B. In conclusion, an init ial fall in GFR is reversible
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even after years of treatment, suggesting that this therapy-induced fall is of
hemodynamic and not structural origin. This initial GFR fall appears to predict the
subsequent degree of renal protection during long-term follow-up.
Future perspectives
The future use of ACE inhibitors as renal protective agents will depend on the results
of large clinical trials proving their efficacy. At this moment substantial clinical proof
is available for the antiproteinuric effects of these agents, however, their alleged renal
protective effect is, in contrast to animal data, far less convincing. With more
inconclusive data from larger intervention studies becoming available, the question even
rises whether it will ever be proven unequivocally that ACE inhibitors indeed possess
a renal protective effect. Why is the efficacy of these drugs so difficult to proof?
First, dilution by non-responders may play an importzrnt role. It has become clear from
several studies that, although a large group of patients may benefit from renal protective
treatment, responses vary considerably between different individuals. A relatively small
group of non-responders or non-compliers on a certain treatment may influence the mean
value of an outcome measure heavily, thereby hiding a potential beneficial effect of such
a treatment. Secondly, inaccuracies in GFR measurements (see Chapter 6) may leave a
true difference between two interventions undetected. With respect to the former it thus
seems of extreme importance to identrfy the patients who would probably benefit the
most from a certain treatment before the actual intervention is started. These patients
may be identified by markers predictive for the magnitude of future renal function
decline. Two of these potential markers, i.e. proteinuria and initial GFR response, have
been discussed in the preceding two chapters. Several other potential predictive markers
are currently evaluated. For instance, plasma homocysteine levels increase with
progressive renal function deterioration [1]. This could be an epiphenomenon, but the
homocysteine level may also be a predictive marker since it might reflect the level of
endothelial dysfunction [2]. T\e plasma lipoprotein(a) tl-p(a)l level is an independent
risk factor for atherosclerosis. In hemodialysis patients the incidence of atherosclerotic
events appears to be higher in hemodialysis patients with increased plasma Lp(a) levels
[3]. It is imaginable that a high Lp(a) level in chronic renal failure might be associated
with a steeper decline in renal function. Interestingly, higher l-p(a) levels are also present
in hypertensive patients with salt-sensitivity, which is another riskfactor with respect to





the hypothesis that progressive renal function decline is a multifactorial process.
Pharmacologic intervention aiming at diminishing serum levels of these potential
markers might be a promising approach in the further prevention of renal function
decline. Future studies should address these issues. Another unresolved issue concerns
the optimum moment of intervention. Is it preferable to staí treatment with an ACE
inhibitor early in the course of the disease at the time the patient has minimal loss of
GFR and treatment responses could still be optimal? Extrapolating animal data, this
seems the most promising approach. However, compliance in these patients without any
compiaints will probably be worse than in patients with more advanced renal disease.
Moreover, in many patients the first contact with a clinician takes place when renal
function deterioration is already substantial. Remarkably however, a recent intervention
study by Kamper et al showed a positive treatment result in patients with a low GFR
t4t.
Genetics may also be important in renal function decline. In the gene codine for
angiotensin converting enzyme an insertion-deletion polymorphism occurs giving rise
to 3 different ACE-genotypes, the II, ID, and the DD ACE-genotype. Phenotypically,
patients with the ll-genotype show low serum ACE-levels, whereas the patients with
DD-genotype have the highest serum-ACE levels [5]. The presence of the DD-genotype
has been shown to be an independent riskfactor for myocardial infarction [ó]. It is
imaginable that this DD-ACE-genotype may also turn out to be a riskfactor for renal
function decline. Even more intriguing is the question whether a potential beneficial
effect of treatment with an ACE-inhibitor is dependent upon the presence of one of these
genotypes. As a final remark, although several advantages of treatment with ACE-
inhibit ion have been highlighted in this thesis, it must be kept in mind that ACE plays
an important role in various organ systems. Our present approach of unselective ACE
rnhibition might have disadvantages in the long run. In this respect it is intriguing that
the ACE DD-genotype, the type with the highest serum ACE, levels, is surprisingly more
frequent in centenarians than in younger people [7]. Leaving open the questions whether
the opposite is also true or whether it is desirable to become a centenarian, this
observation strikes a note of caution with respect to a drastic suppression of serum
(high) ACE levels.
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